Should you buy Insulet stock now?
No, the technical signal for Insulet is currently SELL. Insulet trades at $136.74 as of 8/6/2026. The overall technical signal is: Sell. The technical analysis shows the following: MACD is positive (bullish trend) at 0.109 with falling momentum (signal: 2.127); RSI is at 30.3 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $235.54 points to 72.3% upside. The stock is in a broader downtrend (below SMA50/SMA200). Buying in a downtrend is generally not recommended. This is a technical observation based on current data, not investment advice.
What is the price target for Insulet stock?
The average analyst price target for Insulet is $235.54. The current price is $136.74, which gives an upside of 72.3%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $211.99 and $259.09.
Is Insulet a dividend stock?
No, Insulet does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Insulet stock?
Insulet is rated as a stock with moderate risk. the annual standard deviation is 44.7%, which classifies the stock as moderate risk.
Is Insulet overvalued?
No, Insulet is considered undervalued based on the analyst price target (72.3% upside). Insulet has the following valuation ratios: a P/E ratio of 39.0 (highly valued), a P/S ratio of 4.0, a P/B ratio of 8.8. The analyst price target suggests that the stock is undervalued by 72.3%.
Is Insulet overbought?
No, Insulet is not overbought. RSI is at 30.3 (neutral zone). The technical indicators show: RSI is at 30.3 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 15.7% below the 20-day average (short-term downtrend). In addition, MACD is positive, but momentum is falling.
When is the next Insulet earnings report?
The date of the next earnings report for Insulet has not been published yet. Check the company's investor calendar for updates.
Is Insulet shorted?
Yes, Insulet is shorted with 7.6% of the free float sold short. This is a high level of short selling, which suggests some investors are betting on falling prices. Positive surprises can lead to a moderate short squeeze. Data is updated daily based on official filings with the SEC.
Are insiders buying Insulet stock?
Yes, insiders are net buyers of Insulet – they are buying more shares than they are selling. Over the last 3 months, insiders have made 3 purchases and 3 sales. On a net basis, 610,647 $ worth of shares were bought. Across the last 20 reported transactions, the split is 6 purchases and 14 sales, with a net 924,653 $ bought. Active buyers include Huffines Robert Luther, WEATHERMAN ELIZABETH H, STONESIFER TIMOTHY C. and others. Insider buying is generally seen as a positive signal, because management is putting its own money into the company.
Is Insulet a good stock?
Based on our total score, Insulet is rated as a poor stock with a total score of 31 out of 100. The stock scores below average on value, quality and momentum – it sits at the lower end of the market. The score is made up of Value: 29/100, Quality: 58/100, Momentum: 7/100. In addition: analysts see 72.3% upside to the price target; technical signal: Sell. Whether Insulet is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Insulet stock?
The outlook for Insulet based on current data: the average analyst price target is $235.54 (+72.3%); the stock is in a downtrend (below SMA50 and SMA200); the P/E ratio is 39.0 (high – the market expects growth). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Insulet stock falling?
Insulet is falling right now. The technical indicators show: the price is 15.7% below the 20-day average; short interest is 7.6% (high – many are betting on a decline); insiders have mostly been buying the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Insulet go?
The average analyst price target for Insulet is $235.54, which corresponds to a potential gain of 72.3% from the current price of $136.74. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Insulet fall?
We lack enough history to give a specific floor for Insulet. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Insulet do?
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includ... The company belongs to the Sundhed sector, more specifically the Medicinprodukter industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Insulet as an investment.
Did Insulet raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Insulet. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Insulet making money or losing money?
Yes, Insulet is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 10.4% — which is solid. The operating margin (profit before interest and taxes) is 16.0%. At a P/E ratio of 39.0, you currently pay 39.0 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Insulet go bankrupt?
The bankruptcy risk of Insulet is rated as low. Altman Z2 (a model for assessing financial distress) is 4.04 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 6 — which is average. Debt relative to equity is 155% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Insulet have a lot of debt?
Yes, Insulet has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 155%. For the sundhed sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can Insulet service its debt? Could struggle to service its debt — the interest coverage ratio (how many times earnings can cover interest payments) is -0.2x, and the company has more cash than debt (net cash).
